Clinical trials: Functional Movement Disorder
- Condition Functional Movement Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Huntington Disease
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).
- Trial name
- NCT04556656
- Testing
- Pridopidine
- Where
- 58 sites in United States, Austria and 9 more
- Volunteers
- 499 people
- Sponsor
- Prilenia
Huntington's Disease
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.
- Trial name
- NCT01806896
- Testing
- PF-02545920
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Pfizer
Parkinson's Disease
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease.
- Trial name
- RECOVER (NCT00474058)
- Testing
- Rotigotine
- Where
- 47 sites in United States, Australia and 10 more
- Volunteers
- 287 people
- Sponsor
- UCB Pharma
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Parkinson's Disease
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease.
- Trial name
- NCT00519532
- Testing
- Rotigotine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- UCB Pharma
Parkinson Disease, Depression
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinsons Disease (PD) is caused by a decrease of dopamine in a particular part of the brain. Dopamine is a messenger substance (neurotransmitter) that is used by the cells of the brain (nerve cells) to control and harmonize…
- Trial name
- NCT00297778
- Testing
- Pramipexole
- Where
- 77 sites in Austria, Finland and 11 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson's Disease With End of Dose Wearing Off
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
- Trial name
- NCT00219284
- Testing
- Carbidopa/levodopa/entacapone
- Where
- 42 sites in United States, Puerto Rico
- Volunteers
- 359 people
- Sponsor
- Novartis Pharmaceuticals
Nonhemorrhagic Ischemic Stroke, Motor Function
Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke
The purpose of this study is to evaluate the utility of the S-STREAM as an instrument to assess motor function in subjects who have experienced a nonhemorrhagic ischemic stroke.
- Trial name
- NCT01496885
- Testing
- Observational study
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Daiichi Sankyo
Huntington's Disease
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease.
- Trial name
- NCT02197130
- Testing
- PF-02545920
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 272 people
- Sponsor
- Pfizer
Huntington's Disease
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
- Trial name
- NCT05107128
- Testing
- SAGE-718
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 189 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson's Disease, Tremor
Pilot Study for Automated Deep Brain Stimulation Programming
The clinical utility of deep brain stimulation (DBS) for the treatment of movement disorders such as Parkinson's disease has been well established; however, there is a great disparity in outcomes among DBS recipients due to…
- Conditions
- Parkinson's Disease, Tremor, Bradykinesia
- Trial name
- NCT02046863
- Testing
- Automated Programming
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease (PD)
Observational Study Evaluating Robotic Spinal Mobilization in 16 Parkinson's Disease Participants. The Study Recorded Changes in Mobility, Sit-to-stand Performance, and Pain Scores After a 2-week Intervention With the BackHug Device.
The goal of this completed observational pilot study was to evaluate the immediate and short-term clinical effects of robotic spinal mobilization on motor and non-motor symptoms in community-dwelling adults with Parkinson's…
- Trial name
- NCT07384364
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Pacla Medical Limited